NO20070153L - Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon - Google Patents

Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Info

Publication number
NO20070153L
NO20070153L NO20070153A NO20070153A NO20070153L NO 20070153 L NO20070153 L NO 20070153L NO 20070153 A NO20070153 A NO 20070153A NO 20070153 A NO20070153 A NO 20070153A NO 20070153 L NO20070153 L NO 20070153L
Authority
NO
Norway
Prior art keywords
zcytorl4
binding partners
soluble
antibodies
methods
Prior art date
Application number
NO20070153A
Other languages
English (en)
Norwegian (no)
Inventor
Scott R Presnell
Steven K Burkhead
Steven D Levin
Rolf E Kuestner
Zeren Gao
Stephen R Jaspers
Janine Billsborough
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20070153L publication Critical patent/NO20070153L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20070153A 2004-06-10 2007-01-09 Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon NO20070153L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57880504P 2004-06-10 2004-06-10
PCT/US2005/020521 WO2005123778A2 (en) 2004-06-10 2005-06-10 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
NO20070153L true NO20070153L (no) 2007-03-09

Family

ID=35407029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070153A NO20070153L (no) 2004-06-10 2007-01-09 Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Country Status (11)

Country Link
US (4) US7910540B2 (he)
EP (1) EP1765865A2 (he)
JP (1) JP4903703B2 (he)
CN (1) CN101001871A (he)
AU (1) AU2005254998B2 (he)
BR (1) BRPI0511952A (he)
CA (1) CA2569867A1 (he)
IL (2) IL179356A (he)
MX (1) MXPA06014465A (he)
NO (1) NO20070153L (he)
WO (1) WO2005123778A2 (he)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7324615B2 (en) * 2003-12-15 2008-01-29 Microchip Technology Incorporated Time signal receiver and decoder
US7910540B2 (en) * 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
TW200641353A (en) * 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
CA2621623A1 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
EP1987058B1 (en) * 2006-02-10 2010-05-12 ZymoGenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
EP1996616A1 (en) * 2006-02-10 2008-12-03 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
WO2008131315A2 (en) * 2007-04-20 2008-10-30 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
WO2008133684A1 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
EP2170958A1 (en) * 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
US20110300154A1 (en) * 2007-08-21 2011-12-08 Children's Medical Center Corporation Treatment of airway hyperreactivity
WO2009042162A2 (en) 2007-09-25 2009-04-02 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
JPWO2011096438A1 (ja) * 2010-02-03 2013-06-10 国立大学法人 東京大学 腸疾患の治療方法及び治療用医薬組成物
CN102188707B (zh) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 Il-17抑制剂在制备治疗流感的药物中的用途
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
CN114126638A (zh) * 2019-04-26 2022-03-01 普罗林科斯有限责任公司 缓慢释放的细胞因子偶联物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US20030100051A1 (en) 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO1998049307A1 (en) 1997-05-01 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US20030040471A1 (en) 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
JP2002533058A (ja) 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
US7247442B1 (en) 1998-05-12 2007-07-24 Human Genome Sciences, Inc. Antibodies to HHPEN62 polypeptide
US20020182673A1 (en) 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030199041A1 (en) 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
ES2364086T3 (es) * 1999-07-07 2011-08-24 Zymogenetics, Inc. Receptor de citoquina humana.
EP1240325B1 (en) 1999-12-23 2009-09-30 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US20040048249A1 (en) 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
CA2399943A1 (en) 2000-03-08 2001-09-13 Human Genome Sciences, Inc. Immune system-related polynucleotides, polypeptides, and antibodies
US20040197306A1 (en) 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
AU2001274920A1 (en) 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
AU2001271860A1 (en) 2000-07-06 2002-01-21 Zymogenetics Inc. Murine cytokine receptor
AU2002225714A1 (en) 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US6681210B2 (en) 2001-09-04 2004-01-20 Andrew Jeffrey Kelly Modular service payroll system
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
CA2621623A1 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
EP1987058B1 (en) 2006-02-10 2010-05-12 ZymoGenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods

Also Published As

Publication number Publication date
AU2005254998A1 (en) 2005-12-29
US20070048826A1 (en) 2007-03-01
CN101001871A (zh) 2007-07-18
IL179356A (he) 2011-07-31
BRPI0511952A (pt) 2008-01-29
WO2005123778A2 (en) 2005-12-29
US8268773B2 (en) 2012-09-18
EP1765865A2 (en) 2007-03-28
US20110177083A1 (en) 2011-07-21
US7910540B2 (en) 2011-03-22
IL208859A (he) 2013-01-31
WO2005123778A3 (en) 2006-02-09
US20060002925A1 (en) 2006-01-05
IL179356A0 (en) 2007-03-08
JP4903703B2 (ja) 2012-03-28
AU2005254998B2 (en) 2011-10-27
CA2569867A1 (en) 2005-12-29
US20070048257A1 (en) 2007-03-01
JP2008509227A (ja) 2008-03-27
IL208859A0 (en) 2011-01-31
MXPA06014465A (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20054892D0 (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
EA200800956A1 (ru) Антагонисты il-17a и il-17f и способы их использования
NO20085309L (no) High affinity antibodies to human IL-6 receptor
WO2008039553A8 (en) Soluble il-17rcx4 and methods of using in inflammation
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
WO2004045525A3 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2008134659A8 (en) Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
NO20072514L (no) Loselig ZcytoR21, anti-ZcytoR21-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application